Anne-Sophie de Faucigny
Public Communications Contact presso GETLINK SE
Posizioni attive di Anne-Sophie de Faucigny
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GETLINK SE | Public Communications Contact | 01/10/2022 | - |
Storia della carriera di Anne-Sophie de Faucigny
Precedenti posizioni note di Anne-Sophie de Faucigny
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Direttore/Membro del Consiglio | 01/01/2018 | 01/01/2021 |
Formazione di Anne-Sophie de Faucigny
| Institut d’Études Politiques de Toulouse | Graduate Degree |
Statistiche
Distribuzione geografica
| Francia | 4 |
Posizioni
| Director/Board Member | 1 |
| Public Communications Contact | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 2 |
| Transportation | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GETLINK SE | Transportation |
| Aziende private | 1 |
|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |